Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 11, 2012 - Issue 4
Submit an article Journal homepage
265
Views
14
CrossRef citations to date
0
Altmetric
Drug Safety Evaluations

Clinical overview of the seizure risk of dalfampridine

Sheryl R. HautMontefiore Medical Center, 111 East 210th Street, Bronx, NY 10467, USA+1 718 920 4898; +1 718 882 0216; [email protected]
, MD,
E. Jay BienenThe Curry Rockefeller Group, Tarrytown, NY, USA
, PhD &
Aaron MillerMount Sinai School of Medicine, Department of Neurology, New York, NY, USA
, MD
Pages 651-657 | Published online: 18 Jun 2012

Citations (14)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Michele Jara, Matthew F Sidovar & Herbert R Henney$suffix/text()$suffix/text(). (2015) Prescriber utilization of dalfampridine extended release tablets in multiple sclerosis: a retrospective pharmacy and medical claims analysis. Therapeutics and Clinical Risk Management 11, pages 1-7.
Read now
Michele Jara, Thomas Aquilina, Peter Aupperle & Adrian L Rabinowicz. (2015) Safety profile of dalfampridine extended release in multiple sclerosis: 5-year postmarketing experience in the United States. Drug, Healthcare and Patient Safety 7, pages 169-174.
Read now
Michele Jara, Graham Barker & Herbert R Henney$suffix/text()$suffix/text(). (2013) Dalfampridine extended release tablets: 1 year of postmarketing safety experience in the US. Neuropsychiatric Disease and Treatment 9, pages 365-370.
Read now
Henrik K Mathiesen & Per S Sorensen. (2013) Prolonged-release fampridine improves walking in a proportion of patients with multiple sclerosis. Expert Review of Neurotherapeutics 13:12, pages 1309-1317.
Read now
Scott Weir, Risa Torkin & Herbert R. Henney III. (2013) Pharmacokinetic profile of dalfampridine extended release: clinical relevance in patients with multiple sclerosis. Current Medical Research and Opinion 29:12, pages 1627-1636.
Read now

Articles from other publishers (9)

Masoud Etemadifar, Masih Saboori, Ahmad Chitsaz, Hosein Nouri, Mehri Salari, Reza Khorvash, Donya Sheibani Tehrani & Ali Aghababaee. (2020) The effect of fampridine on the risk of seizure in patients with multiple sclerosis. Multiple Sclerosis and Related Disorders 43, pages 102188.
Crossref
L. Ramió-Torrentà, J.C. Álvarez-Cermeño, R. Arroyo, B. Casanova-Estruch, O. Fernández, J.A. García-Merino, M.A. Hernández, G. Izquierdo, S. Martínez-Yélamos, J. Meca, E. Moral, J. Olascoaga, J.M. Prieto & A. Saiz. (2018) A guide to treating gait impairment with prolonged-release fampridine (Fampyra ® ) in patients with multiple sclerosis. Neurología (English Edition) 33:5, pages 327-337.
Crossref
L. Ramió-Torrentà, J.C. Álvarez-Cermeño, R. Arroyo, B. Casanova-Estruch, O. Fernández, J.A. García-Merino, M.A. Hernández, G. Izquierdo, S. Martínez-Yélamos, J. Meca, E. Moral, J. Olascoaga, J.M. Prieto & A. Saiz. (2018) Guía de tratamiento del deterioro de la marcha con fampridina de liberación prolongada (Fampyra ® ) en pacientes con esclerosis múltiple. Neurología 33:5, pages 327-337.
Crossref
Eric J. Tarcha, Chelsea M. Olsen, Peter Probst, David Peckham, Ernesto J. Muñoz-Elías, James G. Kruger & Shawn P. Iadonato. (2017) Safety and pharmacodynamics of dalazatide, a Kv1.3 channel inhibitor, in the treatment of plaque psoriasis: A randomized phase 1b trial. PLOS ONE 12:7, pages e0180762.
Crossref
Robert Yapundich, Angela Applebee, Francois Bethoux, Myla D. Goldman, George J. Hutton, Michele Mass, Gabriel Pardo, Michael Klingler, Herbert R. HenneyIIIIII, Andrew R. Blight & Enrique J. Carrazana. (2015) Evaluation of Dalfampridine Extended Release 5 and 10 mg in Multiple Sclerosis. International Journal of MS Care 17:3, pages 138-145.
Crossref
Andrew R. Blight, Herbert R. HenneyIIIIII & Ron Cohen. (2014) Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis. Annals of the New York Academy of Sciences 1329:1, pages 33-44.
Crossref
Katherine A. Lyseng-Williamson. (2012) Prolonged-release fampridine: a guide to its use in multiple sclerosis in the EU. Drugs & Therapy Perspectives 28:12, pages 1-4.
Crossref
Katherine A. Lyseng-Williamson. (2012) Prolonged-release fampridine: a guide to its use in multiple sclerosis in the EU. Drugs & Therapy Perspectives 28:12, pages 1-4.
Crossref
Michael D. Egeberg, Caleb Y. Oh & Jacquelyn L. Bainbridge. (2012) Clinical Overview of Dalfampridine: An Agent With a Novel Mechanism of Action to Help With Gait Disturbances. Clinical Therapeutics 34:11, pages 2185-2194.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.